Cargando…
MON-LB054 Activity of Prolactin Receptor Antagonist-Rapamycin Conjugate in Glioblastoma Multiform
Background: Glioblastoma multiform (GBM) is the most common and aggressive primary brain tumor in humans, accounting for approximately 12-15% of all intracranial tumors, with a median survival of 15 months. Although GBM is not considered a hormone sensitive cancer but recent studies showed significa...
Autores principales: | Alkharusi, Amira, Norstedt, Gunnar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551127/ http://dx.doi.org/10.1210/js.2019-MON-LB054 |
Ejemplares similares
-
Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme
por: Alkharusi, Amira, et al.
Publicado: (2016) -
An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation
por: Yu, Shengze, et al.
Publicado: (2019) -
SUN-LB054 Cilengitide Reverts Thyroid Hormones Effects in Bexarotene Treatment of Breast Cancer Cells
por: Díaz Albuja, Johanna, et al.
Publicado: (2019) -
SAT-LB054 Growth Hormone Receptor (GHR) Antagonism Suppresses Hepatocellular Carcinoma Growth in a Syngeneic Mouse Model
por: Mathes, Samuel, et al.
Publicado: (2019) -
Role of Prolactin Receptors in Lymphangioleiomyomatosis
por: Alkharusi, Amira, et al.
Publicado: (2016)